Top Stock To Buy In America Before 2025
It’s still the early days of 2024 and you can still take some drastic steps that can help transform your
financial life in the nearest future. Smart investors are always looking ahead and watching out for smart
ways to earn even more money. Irrespective of what your net worth is right now, you can start looking
out for some superb stocks to buy before 2025.
Let’s examine them now.
Top Stock To Buy In America Before 2025
- Exact Sciences (EXAS)
Exact Sciences (NASDAQ:EXAS) is recognized as one of the stable stocks in the market, primarily due to
its flagship product, Cologuard. This non-invasive colorectal screening test has seen significant
commercial success, reflecting positively on the company’s performance. Currently trading at $61 per
share, EXAS has garnered attention from analysts, with target price projections ranging from $73 to
$130. This outlook suggests a potential return of over 100% for investors.
Also Read
- Top Stock To Buy In America Before 2025
- How To Make Money With Apple Products In America
- How To Make Money With Truth Social Of Donald Trump
- The Future Of Bitcoin
- Best Apps To Make Money In The USA
However, it’s essential to note that Exact Sciences carries a beta of 1.27, indicating it is 27% more
volatile than the overall stock market. While the stock faced challenges in early 2024, the company is
demonstrating resilience and strength in the market, presenting a compelling opportunity for investors
willing to take a contrarian position.
2. Alibaba (BABA)
Another prominent stable stock worth considering is Alibaba (BABA). Despite its current trading price
being approximately $12 below the lowest analyst target, there is significant upside potential, with top
target prices exceeding $220, translating to over 200% upside. Notably, influential investors like Michael
Burry, known for his role in “The Big Short,” have shown confidence in Alibaba, making it the largest
holding at Scion Asset Management.
While investing in Alibaba may seem contrarian given the competitive landscape in Chinese e-
commerce, the company’s positive traction and endorsement from respected stock pickers signal
promising prospects for future growth.
3. Sociedad Quimica y Minera (SQM)
Sociedad Quimica y Minera (NYSE:SQM) mirrors the story of many lithium miners, experiencing robust
operational performance amidst a price collapse in lithium markets. Despite this, the company remains
resilient, mining record volumes and trading at $43 per share, with target prices reaching as high as
$90.50. With a beta of 1.05, SQM offers average volatility and stability to investors.
As a contrarian lithium play, SQM presents an opportunity for investors banking on the inevitable
rebound in lithium prices. With the electric vehicle industry gaining momentum and becoming
increasingly established, companies like SQM are poised for long-term growth and profitability.
4. Darling Ingredients (DAR)
Darling Ingredients (NYSE:DAR) is expected to announce its fourth-quarter earnings on Feb 27, with
strong anticipation for another record-breaking performance. The company’s core ingredients business
is projected to deliver robust growth, reflecting its sustainable approach to repurposing edible waste
byproducts from the meat industry.
Investing in Darling Ingredients appeals to sustainability-minded investors, as the company plays a
crucial role in reducing waste and producing renewable products like renewable diesel. With operations
spanning over 260 facilities worldwide, Darling Ingredients is at the forefront of the sustainable
materials industry.
5. Evotec SE (EVO)
Evotec SE (NASDAQ:EVO) operates in the drug discovery sector and boasts partnerships with leading
biopharmaceutical companies globally. With shares trading at approximately $7, the stock is anticipated
to double in price, reflecting its strong fundamental position and growth potential.
The company’s recent earnings report highlighted a 14% increase in sales to €580.1 million, reaffirming
its positive trajectory. Additionally, Evotec’s collaboration with French firm Owkin to leverage AI for drug
target discovery underscores its commitment to innovation and technological advancement in the
pharmaceutical field. As Evotec continues to prove its capabilities in AI-driven drug discovery, it remains
an attractive option for investors seeking exposure to the biotech industry.
In Conclusion
In all of your investment attempts, make sure you are as careful as possible to put your money only in
safe opportunities. However, here are some stocks some experts believe can do well as we travel down
to 2025. opportunity
